Introduction to therapy of hepatitis C
Article first published online: 10 FEB 2006
Copyright © 2002 American Association for the Study of Liver Diseases
Supplement: National Institutes of Health Consensus Development Conference
Volume 36, Issue Supplement 1, pages S114–S120, November 2002
How to Cite
Lindsay, K. L. (2002), Introduction to therapy of hepatitis C. Hepatology, 36: S114–S120. doi: 10.1002/hep.1840360715
- Issue published online: 10 FEB 2006
- Article first published online: 10 FEB 2006
- National Institutes of Health. Grant Number: N01-DK-9–2325
- National Institutes of Health. Grant Number: U19-AI-4–0038
- 4Definitions Working Group. Biomarkers and Surrogate Endpoints: Advancing Clinical Research and Applications. Sponsored by National Institutes of Health and the Food and Drug Administration, Bethesda, MD, April 15–16, 1999.
- 9for The International Hepatitis Interventional Therapy Group. Durability of sustained virologic response in patients with chronic C after treatment with interferon α-2b alone or in combination with ribavirin [Abstract]. Hepatology 2001; 34: 244A., , , , , , ,
- 10Long-lasting sustained virological response in chronic hepatitis C patients previously treated with 40 kD peginterferon alfa-2a (Pegasys) [Abstract]. Hepatology 2001; 34: 330A., , , , , , , et al.
- 12Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999; 29: 1124–1130., , , , , , , et al.
- 14for the International Hepatitis Interventional Therapy Group (IHIT). Randomised trial of interferon alfa-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352: 1426–1432., , , , , , , et al.,
- 19Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C: is patient gender a confounding factor for sustained virologic response when ribavirin dose is expressed as mg/kg of body weight? [Abstract]. Hepatology 2001; 34: 329A., , , ,
- 22Gastroenterology (in press), , , , , , , et al., for the International Hepatitis Interventional Therapy Group. Adherence to combination therapy enhances sustained response in genotype-1 infected patients with chronic hepatitis C infection.